STOCK TITAN

Celanese Announces a Research Agreement with Johns Hopkins University to Advance Sustained Ocular Drug Delivery to the Suprachoroidal Space

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Celanese Corporation (NYSE: CE) has announced a collaboration with Johns Hopkins University Department of Ophthalmology to study sustained drug delivery to the eye's suprachoroidal space. This approach aims to reduce the frequency of ocular injections for retinal disorders. Utilizing the VitalDose® Drug Delivery Platform, the bioinert implant promises over six months of continuous therapeutic delivery, enhancing patient compliance. The Celanese Development & Feasibility Lab will conduct parts of the research, supporting the development of long-acting drug delivery systems.

Celanese remains committed to improving healthcare solutions in ophthalmology and other fields.

Positive
  • Collaboration with Johns Hopkins University aims to innovate treatment for retinal disorders.
  • The VitalDose® platform offers over six months of drug delivery, improving patient compliance.
  • The Development & Feasibility Lab supports accelerated drug delivery development.
Negative
  • None.

Work may provide insights to help improve treatment paradigm for retinal disorders

DALLAS--(BUSINESS WIRE)-- Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, today announced an agreement with Johns Hopkins University Department of Ophthalmology to collaborate on a study of sustained drug delivery to the suprachoroidal space in the eye.

Direct administration of therapeutics to the suprachoroidal space is growing more common as an approach for the treatment of retinal disorders. Treatment currently consists of frequent ocular injections performed at the physician’s office. A bioinert implant based on the VitalDose® platform can provide sustained ocular drug delivery for greater than six months, providing an alternative approach for reliable, continuous dosing and reducing the treatment burden for the patient.

The VitalDose® Drug Delivery Platform independently has proven biocompatibility and achieves greater than six months release of mAbs, peptides, small molecules and RNAi therapeutics, making it suitable for delivering a variety of therapeutics used for ophthalmologic conditions.

“Our collaboration with John Hopkins Department of Ophthalmology allows us to seek out scientific advancements with potential to improve patient health in ophthalmology,” said Cyonna Holmes, global business strategy leader for ophthalmology at Celanese. “The VitalDose® technology platform has potential well beyond its present commercialized applications. That’s why we explore collaborations that cross traditional boundaries with the goal to realize improvements in patient compliance and health through innovative treatments in areas like ophthalmology, women’s health, rare diseases and the central nervous system.”

Scientists at the Celanese Development & Feasibility Lab will independently conduct portions of the planned research in this dedicated pharmaceutical facility. Since opening in 2021, the lab has provided customized support to accelerate customers’ long-acting drug delivery development programs. Services include material characterization; injection molding, hot-melt extrusion and other prototyping capabilities; monolithic or multi-layer drug-loaded prototypes; in vitro characterization and drug release studies; and tooling design and development.

The VitalDose® Drug Delivery Platform provides reliable, controlled-release performance and has a long history of use in approved parenteral drug products in the United States and Europe. For more information on Celanese VitalDose® technology, visit www.vitaldose.com.

About Celanese
Celanese Corporation is a global chemical leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese's global chemistry, technology, and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 13,000 employees worldwide and had 2021 net sales of $8.5 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com.

Investor Relations

Brandon Ayache

+1 972 443 8509

brandon.ayache@celanese.com

Media Relations – Global

Brian Bianco

+1 972 443 4400

media@celanese.com

Media Relations Europe (Germany)

Petra Czugler

+49 69 45009 1206

petra.czugler@celanese.com

Source: Celanese Corporation

FAQ

What is the collaboration between Celanese and Johns Hopkins about?

Celanese is collaborating with Johns Hopkins University to study sustained drug delivery to the suprachoroidal space for treating retinal disorders.

How does the VitalDose® platform improve treatment for retinal disorders?

The VitalDose® platform provides over six months of continuous drug delivery, significantly reducing the need for frequent ocular injections.

What is the focus of Celanese's Development & Feasibility Lab?

The lab focuses on supporting the development of long-acting drug delivery systems, including materials characterization and prototyping.

What are the potential benefits of the collaboration for patients?

The collaboration aims to improve patient health by enhancing treatment compliance and reducing the burden of frequent injections.

Celanese Corporation

NYSE:CE

CE Rankings

CE Latest News

CE Stock Data

7.43B
108.87M
0.41%
95.43%
4.64%
Chemicals
Plastic Material, Synth Resin/rubber, Cellulos (no Glass)
Link
United States of America
IRVING